|
|
# 2024 ShieldYd Solutions |
|
ShieldYd addresses the challenge of off-target effects in antibody-based therapeutics, which can cause undesirable side effects in treatments for cancer and age-related diseases. This innovative approach includes antibody drugs designed to precisely target cancer and senescent cells, along with genetically encoded executioner proteins. By integrating advanced control mechanisms, ShieldYd enhances both safety and efficacy, minimising side effects while delivering potent treatments. This breakthrough represents a paradigm shift in antibody therapies, offering more reliable and precise treatment options to revolutionise patient care
Following her BA/MSci in Biochemistry at the University of Cambridge, Eleanor Sheekey completed her PhD with Professor Masashi Narita's lab at Cancer Research UK - Cambridge Institute, where her work specialised in the biochemistry of senescent cells. Following this, she returned to the Biochemistry Department to work with Marc de la Roche to make safe and effective antibody-based therapeutics. Alongside her academic pursuits, Eleanor is the creator of “The Sheekey Science Show”, a popular YouTube channel explaining complex aging research to a broader audience in an engaging and fun manner. She is currently in RIKEN, Kobe, Japan, investigating tissue aging. more
Student developing novel therapeutic strategies for targeting cancers.more
Nanyang Technological University
Targeted antimicrobial treatment for resistant infections
